2021年1月,国际癌症研究机构团队在美国癌症学会旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表了最新的全球癌症统计报告。该报告阐述了2020年36种癌症在全球185个国家的发病和死亡情况,分析了其性别和地...2021年1月,国际癌症研究机构团队在美国癌症学会旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表了最新的全球癌症统计报告。该报告阐述了2020年36种癌症在全球185个国家的发病和死亡情况,分析了其性别和地理分布差异,并根据2020年估计的发病和死亡数据预估了2040年全球可能面临的癌症疾病负担。北京大学肿瘤医院流行病学研究室团队对该报告进行了整理,结合中国主要癌症的流行趋势与疾病负担对该报告进行简要解读。展开更多
Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of ...Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of cancer burden worldwide and in China and compares the cancer data of China with those of other regions.Methods:We conducted a descriptive secondary analysis of the GLOBOCAN 2020 data.To depict the changing global profile of the leading cancer types in 2020 compared with 2018,we extracted the numbers of cases and deaths in 2018 from GLOBOCAN 2018.We also obtained cancer incidence and mortality from the 2015 National Cancer Registry Report in China when sorting the leading cancer types by new cases and deaths.For the leading cancer types according to sex in China,we summarized the estimated numbers of incidence and mortality,and calculated China’s percentage of the global new cases and deaths.Results:Breast cancer displaced lung cancer to become the most leading diagnosed cancer worldwide in 2020.Lung,liver,stomach,breast,and colon cancers were the top five leading causes of cancer-related death,among which liver cancer changed from the third-highest cancer mortality in 2018 to the second-highest in 2020.China accounted for 24%of newly diagnosed cases and 30%of the cancer-related deaths worldwide in 2020.Among the 185 countries included in the database,China’s age-standardized incidence rate(204.8 per 100,000)ranked 65th and the age-standardized mortality rate(129.4 per 100,000)ranked 13th.The two rates were above the global average.Lung cancer remained the most common cancer type and the leading cause of cancer death in China.However,breast cancer became the most frequent cancer type among women if the incidence was stratified by sex.Incidences of colorectal cancer and breast cancer increased rapidly.The leading causes of cancer death varied minimally in ranking from 2015 to 2020 in China.Gastrointestinal cancers,including stomach,colorectal,liver,and esophageal cancers,contributed to a massive bu展开更多
Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide r...Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide reference for policy planning and contribute to improving cancer control measures.In this study,we reviewed the rates and trends of cancer incidence and mortality and disability-adjusted life year(DALY)burden in China,and compared them with those in the United States(US)and the United Kingdom(UK).Methods:Cancer incidence,mortality,and DALY data for China,US and UK were obtained fromtheGLOBOCAN2020 online database,Global Burden of Disease(GBD)2019 study,and Cancer Incidence in Five Continents plus database(CI5 plus).Trends of cancer incidence and mortality in China,US,and UK were analyzed using Joinpoint regression models to calculate annual percent changes(APCs)and identify the best-fitting joinpoints.Results:An estimated 4,568,754 newly diagnosed cancer cases and 3,002,899 cancer deaths occurred in China in 2020.Additionally,cancers resulted in 67,340,309 DALYs in China.Compared to the US and UK,China had lower cancer incidence but higher cancer mortality andDALY rates.Furthermore,the cancer spectrum of China was changing,with a rapid increase incidence and burden of lung,breast,colorectal,and prostate cancer in addition to a high incidence and heavy burden of liver,stomach,esophageal,and cervical cancer.Conclusions:The cancer spectrum of China is changing from a developing country to a developed country.Population aging and increase of unhealthy lifestyles would continue to increase the cancer burden of China.Therefore,the Chinese authorities should adjust the national cancer control program with reference to the practices of cancer control which have been well-established in the developed countries,and taking consideration of the diversity of cancer types by of different regions in China at the same time.展开更多
背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disabi...背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。展开更多
Background:Globally,colorectal cancer(CRC)imposes a substantial burden on healthcare systems and confers considerable medical expenditures.We aimed to evaluate the global and regional burden in epidemiological trends ...Background:Globally,colorectal cancer(CRC)imposes a substantial burden on healthcare systems and confers considerable medical expenditures.We aimed to evaluate the global and regional burden in epidemiological trends and factors associated with the incidence and mortality of CRC.Methods:We used data from the GLOBOCAN database to estimate CRC incidence and mortality worldwide in 2020 and their association with the human development index(HDI).Trends of age-standardized rates of incidence and mortality in 60 countries(2000–2019)were evaluated by Joinpoint regression analysis using data of Global Burden of Disease 2019.The association between exposure to country-level lifestyle,metabolic and socioeconomic factors obtained from the World Health Organization Global Health Observatory and World Bank DataBank data and CRC incidence and mortality was determined by multivariable linear regression.Results:CRC incidence and mortality varied greatly in the 60 selected countries,and much higher incidence and mortality were observed in countries with higher HDIs,and vice versa.From 2000 to 2019,significant increases of incidence and mortality were observed for 33 countries(average annual percent changes[AAPCs],0.24–3.82)and 18 countries(AAPCs,0.41–2.22),respectively.A stronger increase in incidence was observed among males(AAPCs,0.36–4.54)and individuals<50 years(AAPCs,0.56–3.86).Notably,15 countries showed significant decreases in both incidence(AAPCs,0.24 to2.19)and mortality(AAPCs,0.84 to2.74).A significant increase of incidence among individuals<50 years was observed in 30 countries(AAPCs,0.28–3.62).Countries with higher incidence were more likely to have a higher prevalence of alcohol drinking,higher level of cholesterol level,higher level of unemployment,and a poorer healthcare system.Conclusions:Some high-HDI countries showed decreasing trends in CRC incidence and mortality,whereas developing countries that previously had low disease burden showed significantly increased incidence and mortality trends,especi展开更多
2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症...2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症负担差异,并对至2050年的癌症负担进行了预测。GLOBOCAN 2022数据显示,2022年全球估计新发癌症19976499例,9743832例癌症患者死亡。肺癌是全球首位常见癌症,2022年发病例数为2480675例,占总体癌症发病的12.4%。其次是乳腺癌(11.5%)、结直肠癌(9.6%)、前列腺癌(7.3%)和胃癌(4.9%)。肺癌仍是导致癌症死亡的首要原因,估计有1817469例死亡,占总体癌症死亡的18.7%。其次是结直肠癌(9.3%)、肝癌(7.8%)、乳腺癌(6.8%)和胃癌(6.8%)。基于人口统计学的预测表明,到2050年,全球新增癌症病例将达到3528.1万例,与2022年相比增加76.6%。全球癌症发病和死亡具有明显的地区和性别差异。本文对更新的数据库中主要内容进行整理并加以解读。展开更多
2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差...2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差异,同时根据2022年的发病与死亡数据预测了2050年全球癌症疾病负担。基于我国癌症流行现状及防治目标,北京大学肿瘤医院流行病学研究室团队对该报告进行了整理与解读。展开更多
目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提...目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提供参考。方法系统整理并分析了GLOBOCAN 2022中的统计数据,对分年龄、性别、类型及地区的癌症发病和死亡情况进行全面解读,重点对中国癌症与世界癌症水平的比较进行分析,并结合可能的危险因素流行情况和现行癌症预防及控制措施进行讨论。结果①从全球看,2022年全球新发癌症病例1997.6万例、标化发病率196.9/10万,死亡病例974.4万例、标化死亡率91.7/10万;所有癌症的标化发病率在欧洲最高(268.1/10万)、东南亚最低(109.6/10万),所有癌症的标化死亡率在欧洲最高(106.3/10万)、东南亚最低(71.0/10万);全球发病前3位的癌症分别是肺癌、乳腺癌、结直肠癌,死亡前3位的癌症分别是肺癌、结直肠癌、肝癌;所有癌症的标化发病率和标化死亡率均随年龄增长呈上升趋势。全球男性的新发病例数和标化发病率以及癌症死亡例数和标化死亡率均高于女性,肺癌和乳腺癌分别是男性和女性的第1位常见癌症和第1位癌症死亡原因。②在中国,2022年中国癌症新发病例482.5万例、标化发病率为201.6/10万,死亡病例257.4万例、标化死亡率96.5/10万,按标化发病率和标化死亡率顺位排序在185个国家中均位于第65位,癌症新发病例数顺位前3位者分别为肺癌、结直肠癌及甲状腺癌,癌症死亡例数顺位前3位者分别为肺癌、肝癌及胃癌。结论2022年全球癌症标化发病率和标化死亡率均较2020年(196.9/10万比201.0/10万、91.7/10万比100.7/10万)有所下降。我国新发癌症第1位与全球一致(均是肺癌),而第2、3位与全球不同,我国第2、3位分别是结直肠癌和甲状腺癌,全球第2、3位分别是乳�展开更多
目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制...目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制中心国家慢性病和非传染性疾病控制与预防中心研究团队在Lancet Public Health上发表的《2005–2020年中国癌症负担变化》这2篇报告中的结果进行整理并做简要解读,分析了2018–2022年肝癌在全球和中国的流行趋势变化、2022年全球不同人类发展指数和收入水平国家肝癌的ASIRW(世界标准人口年龄标准化发病率)和ASMRW(世界标准人口年龄标准化死亡率)变化情况、2022年全球和中国不同年龄段肝癌的发病和死亡情况以及2005–2020年中国肝癌的疾病负担变化。结果2022年全球肝癌新发病例865269例,死亡病例757948例,是全球第6大新发癌症及第3大癌症致死病因。全球和中国2018–2022年肝癌发病和死亡情况均趋于平稳或呈下降趋势,它们在男性人群中均高于女性,而且在中国总体人群和男性人群中均明显高于全球。2022年肝癌ASIRW和ASMRW在高人类发展指数和中等偏上收入水平国家人群中均最高。全球及中国2022年的肝癌ASIRW和ASMRW均随年龄增长而增高。我国2005–2020年所有年龄段死亡例数、ASMRW、生命损失年和年龄标准化生命损失年率的平均年度百分比变化均为负值,提示各指标均呈现下降趋势,而2020年我国男性和女性的肝癌ASMRW均随年龄增长而增高。结论肝癌在中国和全球仍面临巨大的疾病负担,在未来贯彻落实肝癌一级和二级预防策略仍是防治肝癌的重要措施,同时仍需继续做好肝癌全程多学科规范化管理。展开更多
2024年4月,世界卫生组织国际癌症研究机构团队在CA:A Cancer Journal for Clinicians杂志发表了2022年全球恶性肿瘤统计报告,重点阐述了世界185个国家或地区36种恶性肿瘤的发病和死亡情况,并分析不同性别、地理区域和以人类发展指数划...2024年4月,世界卫生组织国际癌症研究机构团队在CA:A Cancer Journal for Clinicians杂志发表了2022年全球恶性肿瘤统计报告,重点阐述了世界185个国家或地区36种恶性肿瘤的发病和死亡情况,并分析不同性别、地理区域和以人类发展指数划分的不同经济区域的差异。据估计,2022年全球新增1996.5万恶性肿瘤新发病例和973.7万死亡病例。全球发病前5位的癌种分别为肺癌(248.0万,12.4%)、女性乳腺癌(229.6万,11.5%)、结直肠癌(192.6万,9.6%)、前列腺癌(146.7万,7.3%)和胃癌(96.8万,4.9%)。死亡前5位的癌种分别为肺癌(181.7万,18.7%)、结直肠癌(90.4万,9.3%)、肝癌(75.8万,7.8%)、女性乳腺癌(66.6万,6.9%)和胃癌(66.0万,6.8%)。基于当前人口特征估计,至2050年全球恶性肿瘤新发病例将超过3500万。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国恶性肿瘤发病和死亡现况进行简要解读。展开更多
Background: Despite the decline in the incidence and mortality rates of gastric cancer (GC), the impact of demographic transition on the global burden of GC remains unclear. The current study aimed to estimate the glo...Background: Despite the decline in the incidence and mortality rates of gastric cancer (GC), the impact of demographic transition on the global burden of GC remains unclear. The current study aimed to estimate the global disease burden through 2040 by age, sex, and region. Methods: GC data for incident cases and deaths by age group and sex were taken from The Global Cancer Observatory (GLOBOCAN) 2020. The incidence and mortality rates were predicted through 2040 by fitting a linear regression model over the most recent trend period with the Cancer Incidence in Five Continents (CI5) data. Results: The global population will grow to 9.19 billion by 2040, accompanied by increasing population ageing. The incidence and mortality rates of GC will show a persistent decrease, with an annual percent change of -0.57% for males and -0.65% for females. East Asia and North America will have the highest and lowest age standardized rates, respectively. A slowdown in the growth of incident cases and deaths will be observed worldwide. The proportion of young and middle-aged individuals will decline, while the percentage of the elderly will increase, and the number of males will be almost twice the number of females. East Asia and high human development index (HDI) regions will be heavily burdened by GC. East Asia had 59.85% of the new cases and 56.23% of deaths in 2020;these will increase to 66.93% and 64.37% by 2040, respectively. The interaction between population growth, the change in ageing structure and the decline in incidence and mortality rates will lead to an increased burden of GC. Conclusions: Ageing and population growth will offset the decline in the incidence and mortality rate of GC, resulting in a substantial increase in the number of new cases and deaths. The age structure will continue to change, especially in high HDI regions, requiring more targeted prevention strategies in the future.展开更多
癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地...癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地区中的36种癌症发病率、死亡率和患病率等相关数据,并且数据会不断更新,为研究者做疾病预测及疾病负担分析提供了宝贵的资料。本文通过对GLOBOCAN数据库架构及数据分析方法的详细介绍,帮助需要的研究者快速获取数据库相关知识,高效快捷地开展相关研究。展开更多
BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwid...BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwide profile of digestive cancer incidence,mortality and corresponding trends among 20–39-year-olds,with major patterns highlighted by age,sex,development level,and geographical region.METHODS I performed a population-based study to quantify the burden of young adult digestive cancers worldwide.Global,regional,sex,and country-specific data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2020 were extracted from the GLOBOCAN Cancer Today database.To assess long-term trends in young adult digestive cancer,cancer incidence data and mortality data were obtained from the Cancer in Five Continents Plus database and the World Health Organization mortality database,respectively.The associations between the human development index(HDI)and digestive cancer burden in young adults were evaluated by linear regression analyses.RESULTS In 2020,there were an estimated 19292789 new cancer cases,resulting in 9958133 deaths worldwide,which equated to an age-standardized incidence rate(ASIR)of 5.16 and age-standardized mortality rate(ASMR)of 3.04,accounting for 12.24%of all new cancer cases and 25.26%of all cancer deaths occurring in young adults.The burden was disproportionally greater among males,with male:female ratios of 1.34 for incidence and 1.58 for mortality.The ASIRs were 2.1,1.4,and 1.0 per 100000 people per year,whereas the ASMRs were 0.83,1.1,and 0.62 per 100000 people per year for colorectal,liver,and gastric cancer,respectively.When assessed by geographical region and HDI levels,the cancer profile varied substantially,and a strong positive correlation between the mortality-to-incidence ratio of digestive cancer and HDI ranking was found(R^(2)=0.7388,P<0.001).CONCLUSION The most common digestive cancer types are colorectal,liver and gastric cancer.The global digestiv展开更多
近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年...近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年将新增1810万癌症病例和970万癌症死亡病例。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国肿瘤登记现况进行简要解读。展开更多
文摘2021年1月,国际癌症研究机构团队在美国癌症学会旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表了最新的全球癌症统计报告。该报告阐述了2020年36种癌症在全球185个国家的发病和死亡情况,分析了其性别和地理分布差异,并根据2020年估计的发病和死亡数据预估了2040年全球可能面临的癌症疾病负担。北京大学肿瘤医院流行病学研究室团队对该报告进行了整理,结合中国主要癌症的流行趋势与疾病负担对该报告进行简要解读。
文摘Background:Cancer is one of the leading causes of death globally,but its burden is not uniform.GLOBOCAN 2020 has newly updated the estimates of cancer burden.This study summarizes the most recent changing profiles of cancer burden worldwide and in China and compares the cancer data of China with those of other regions.Methods:We conducted a descriptive secondary analysis of the GLOBOCAN 2020 data.To depict the changing global profile of the leading cancer types in 2020 compared with 2018,we extracted the numbers of cases and deaths in 2018 from GLOBOCAN 2018.We also obtained cancer incidence and mortality from the 2015 National Cancer Registry Report in China when sorting the leading cancer types by new cases and deaths.For the leading cancer types according to sex in China,we summarized the estimated numbers of incidence and mortality,and calculated China’s percentage of the global new cases and deaths.Results:Breast cancer displaced lung cancer to become the most leading diagnosed cancer worldwide in 2020.Lung,liver,stomach,breast,and colon cancers were the top five leading causes of cancer-related death,among which liver cancer changed from the third-highest cancer mortality in 2018 to the second-highest in 2020.China accounted for 24%of newly diagnosed cases and 30%of the cancer-related deaths worldwide in 2020.Among the 185 countries included in the database,China’s age-standardized incidence rate(204.8 per 100,000)ranked 65th and the age-standardized mortality rate(129.4 per 100,000)ranked 13th.The two rates were above the global average.Lung cancer remained the most common cancer type and the leading cause of cancer death in China.However,breast cancer became the most frequent cancer type among women if the incidence was stratified by sex.Incidences of colorectal cancer and breast cancer increased rapidly.The leading causes of cancer death varied minimally in ranking from 2015 to 2020 in China.Gastrointestinal cancers,including stomach,colorectal,liver,and esophageal cancers,contributed to a massive bu
文摘Background:Cancer is one of the leading causes of death and a main economic burden in China.Investigating the differences in cancer patterns and control strategies between China and developed countries could provide reference for policy planning and contribute to improving cancer control measures.In this study,we reviewed the rates and trends of cancer incidence and mortality and disability-adjusted life year(DALY)burden in China,and compared them with those in the United States(US)and the United Kingdom(UK).Methods:Cancer incidence,mortality,and DALY data for China,US and UK were obtained fromtheGLOBOCAN2020 online database,Global Burden of Disease(GBD)2019 study,and Cancer Incidence in Five Continents plus database(CI5 plus).Trends of cancer incidence and mortality in China,US,and UK were analyzed using Joinpoint regression models to calculate annual percent changes(APCs)and identify the best-fitting joinpoints.Results:An estimated 4,568,754 newly diagnosed cancer cases and 3,002,899 cancer deaths occurred in China in 2020.Additionally,cancers resulted in 67,340,309 DALYs in China.Compared to the US and UK,China had lower cancer incidence but higher cancer mortality andDALY rates.Furthermore,the cancer spectrum of China was changing,with a rapid increase incidence and burden of lung,breast,colorectal,and prostate cancer in addition to a high incidence and heavy burden of liver,stomach,esophageal,and cervical cancer.Conclusions:The cancer spectrum of China is changing from a developing country to a developed country.Population aging and increase of unhealthy lifestyles would continue to increase the cancer burden of China.Therefore,the Chinese authorities should adjust the national cancer control program with reference to the practices of cancer control which have been well-established in the developed countries,and taking consideration of the diversity of cancer types by of different regions in China at the same time.
文摘背景与目的 癌症是中国人群的主要致死原因之一,也是中国的主要经济负担。研究中国与发达国家在癌症模式和控制策略上的差异,可为政策规划提供参考,有助于改善癌症防控措施。本研究回顾了中国癌症发病率、死亡率和伤残调整生命年(disability-adjusted life year,DALY)负担的比率及趋势,并与美国(United States,US)和英国(United Kingdom,UK)进行了比较。方法 本研究从GLOBOCAN 2020在线数据库、2019年全球疾病负担(global burden of disease,GBD)研究和五大洲癌症发病率plus数据库(Cancer Incidence in Five Continents plus database,CI5 plus)中获取中国、美国和英国的癌症发病率、死亡率和DALY数据。使用Joinpoint回归模型分析中国、美国和英国癌症发病率和死亡率的趋势,计算年度百分比变化(annual percent change,APC),并确定最佳拟合连接点。结果 2020年估算的中国新发癌症病例为4,568,754例,癌症死亡病例为3,002,899例。此外,在中国,癌症引起的DALY为67,340,309。与美国和英国相比,中国的癌症发病率更低,但癌症死亡率和DALY率更高。此外,中国的癌症谱正在发生变化,除了肝癌、胃癌、食管癌和宫颈癌的发病率高和负担沉重外,肺癌、乳腺癌、结直肠癌和前列腺癌的发病率和负担正在迅速增长。结论 中国的癌症谱正在从发展中国家向发达国家转变。人口老龄化和不健康生活方式将继续增加中国的癌症负担。因此,中国应参考发达国家已建立的癌症防控策略,并结合中国不同地区癌症类型的多样性,调整国家癌症控制政策。
基金the Natural Science Foundation of Beijing Municipality(No.7202169)the Beijing Nova Program of Science and Technology(No.Z191100001119065)the CAMS Innovation Fund for Medical Sciences(No.2017-I2M-1-006).
文摘Background:Globally,colorectal cancer(CRC)imposes a substantial burden on healthcare systems and confers considerable medical expenditures.We aimed to evaluate the global and regional burden in epidemiological trends and factors associated with the incidence and mortality of CRC.Methods:We used data from the GLOBOCAN database to estimate CRC incidence and mortality worldwide in 2020 and their association with the human development index(HDI).Trends of age-standardized rates of incidence and mortality in 60 countries(2000–2019)were evaluated by Joinpoint regression analysis using data of Global Burden of Disease 2019.The association between exposure to country-level lifestyle,metabolic and socioeconomic factors obtained from the World Health Organization Global Health Observatory and World Bank DataBank data and CRC incidence and mortality was determined by multivariable linear regression.Results:CRC incidence and mortality varied greatly in the 60 selected countries,and much higher incidence and mortality were observed in countries with higher HDIs,and vice versa.From 2000 to 2019,significant increases of incidence and mortality were observed for 33 countries(average annual percent changes[AAPCs],0.24–3.82)and 18 countries(AAPCs,0.41–2.22),respectively.A stronger increase in incidence was observed among males(AAPCs,0.36–4.54)and individuals<50 years(AAPCs,0.56–3.86).Notably,15 countries showed significant decreases in both incidence(AAPCs,0.24 to2.19)and mortality(AAPCs,0.84 to2.74).A significant increase of incidence among individuals<50 years was observed in 30 countries(AAPCs,0.28–3.62).Countries with higher incidence were more likely to have a higher prevalence of alcohol drinking,higher level of cholesterol level,higher level of unemployment,and a poorer healthcare system.Conclusions:Some high-HDI countries showed decreasing trends in CRC incidence and mortality,whereas developing countries that previously had low disease burden showed significantly increased incidence and mortality trends,especi
文摘2024年2月国际癌症研究机构(International Agency for Research on Cancer,IARC)发布了最新的全球癌症统计数据GLOBOCAN 2022,估计了全球185个国家/地区的36种癌症发病数/率、死亡数/率等最新数据,描述了不同国家/地区和性别下的癌症负担差异,并对至2050年的癌症负担进行了预测。GLOBOCAN 2022数据显示,2022年全球估计新发癌症19976499例,9743832例癌症患者死亡。肺癌是全球首位常见癌症,2022年发病例数为2480675例,占总体癌症发病的12.4%。其次是乳腺癌(11.5%)、结直肠癌(9.6%)、前列腺癌(7.3%)和胃癌(4.9%)。肺癌仍是导致癌症死亡的首要原因,估计有1817469例死亡,占总体癌症死亡的18.7%。其次是结直肠癌(9.3%)、肝癌(7.8%)、乳腺癌(6.8%)和胃癌(6.8%)。基于人口统计学的预测表明,到2050年,全球新增癌症病例将达到3528.1万例,与2022年相比增加76.6%。全球癌症发病和死亡具有明显的地区和性别差异。本文对更新的数据库中主要内容进行整理并加以解读。
文摘2024年4月,国际癌症研究机构在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布了最新全球癌症统计报告,全面阐述了2022年全球185个国家36种癌症的发病、死亡与疾病负担情况,描述了其中20个地区10种主要癌症的地理分布差异,同时根据2022年的发病与死亡数据预测了2050年全球癌症疾病负担。基于我国癌症流行现状及防治目标,北京大学肿瘤医院流行病学研究室团队对该报告进行了整理与解读。
文摘目的通过及时了解2024年4月在《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发表的《2022全球癌症统计报告:全球185个国家36种癌症发病率和死亡率估计》中报告的全球癌症最新统计数据,为我国及时调整癌症预防及控制措施提供参考。方法系统整理并分析了GLOBOCAN 2022中的统计数据,对分年龄、性别、类型及地区的癌症发病和死亡情况进行全面解读,重点对中国癌症与世界癌症水平的比较进行分析,并结合可能的危险因素流行情况和现行癌症预防及控制措施进行讨论。结果①从全球看,2022年全球新发癌症病例1997.6万例、标化发病率196.9/10万,死亡病例974.4万例、标化死亡率91.7/10万;所有癌症的标化发病率在欧洲最高(268.1/10万)、东南亚最低(109.6/10万),所有癌症的标化死亡率在欧洲最高(106.3/10万)、东南亚最低(71.0/10万);全球发病前3位的癌症分别是肺癌、乳腺癌、结直肠癌,死亡前3位的癌症分别是肺癌、结直肠癌、肝癌;所有癌症的标化发病率和标化死亡率均随年龄增长呈上升趋势。全球男性的新发病例数和标化发病率以及癌症死亡例数和标化死亡率均高于女性,肺癌和乳腺癌分别是男性和女性的第1位常见癌症和第1位癌症死亡原因。②在中国,2022年中国癌症新发病例482.5万例、标化发病率为201.6/10万,死亡病例257.4万例、标化死亡率96.5/10万,按标化发病率和标化死亡率顺位排序在185个国家中均位于第65位,癌症新发病例数顺位前3位者分别为肺癌、结直肠癌及甲状腺癌,癌症死亡例数顺位前3位者分别为肺癌、肝癌及胃癌。结论2022年全球癌症标化发病率和标化死亡率均较2020年(196.9/10万比201.0/10万、91.7/10万比100.7/10万)有所下降。我国新发癌症第1位与全球一致(均是肺癌),而第2、3位与全球不同,我国第2、3位分别是结直肠癌和甲状腺癌,全球第2、3位分别是乳�
文摘目的了解全球及中国最新的肝癌流行病学特征情况。方法本团队通过对2024年4月国际癌症研究机构团队在其旗下权威杂志《临床医师癌症杂志》(CA:A Cancer Journal for Clinicians)发布的《最新全球癌症统计报告》及近期中国疾病预防控制中心国家慢性病和非传染性疾病控制与预防中心研究团队在Lancet Public Health上发表的《2005–2020年中国癌症负担变化》这2篇报告中的结果进行整理并做简要解读,分析了2018–2022年肝癌在全球和中国的流行趋势变化、2022年全球不同人类发展指数和收入水平国家肝癌的ASIRW(世界标准人口年龄标准化发病率)和ASMRW(世界标准人口年龄标准化死亡率)变化情况、2022年全球和中国不同年龄段肝癌的发病和死亡情况以及2005–2020年中国肝癌的疾病负担变化。结果2022年全球肝癌新发病例865269例,死亡病例757948例,是全球第6大新发癌症及第3大癌症致死病因。全球和中国2018–2022年肝癌发病和死亡情况均趋于平稳或呈下降趋势,它们在男性人群中均高于女性,而且在中国总体人群和男性人群中均明显高于全球。2022年肝癌ASIRW和ASMRW在高人类发展指数和中等偏上收入水平国家人群中均最高。全球及中国2022年的肝癌ASIRW和ASMRW均随年龄增长而增高。我国2005–2020年所有年龄段死亡例数、ASMRW、生命损失年和年龄标准化生命损失年率的平均年度百分比变化均为负值,提示各指标均呈现下降趋势,而2020年我国男性和女性的肝癌ASMRW均随年龄增长而增高。结论肝癌在中国和全球仍面临巨大的疾病负担,在未来贯彻落实肝癌一级和二级预防策略仍是防治肝癌的重要措施,同时仍需继续做好肝癌全程多学科规范化管理。
文摘2024年4月,世界卫生组织国际癌症研究机构团队在CA:A Cancer Journal for Clinicians杂志发表了2022年全球恶性肿瘤统计报告,重点阐述了世界185个国家或地区36种恶性肿瘤的发病和死亡情况,并分析不同性别、地理区域和以人类发展指数划分的不同经济区域的差异。据估计,2022年全球新增1996.5万恶性肿瘤新发病例和973.7万死亡病例。全球发病前5位的癌种分别为肺癌(248.0万,12.4%)、女性乳腺癌(229.6万,11.5%)、结直肠癌(192.6万,9.6%)、前列腺癌(146.7万,7.3%)和胃癌(96.8万,4.9%)。死亡前5位的癌种分别为肺癌(181.7万,18.7%)、结直肠癌(90.4万,9.3%)、肝癌(75.8万,7.8%)、女性乳腺癌(66.6万,6.9%)和胃癌(66.0万,6.8%)。基于当前人口特征估计,至2050年全球恶性肿瘤新发病例将超过3500万。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国恶性肿瘤发病和死亡现况进行简要解读。
基金supported by a grant from the Summit Talent Plan of Beijing Hospitals Authority(No.DFL20181103).
文摘Background: Despite the decline in the incidence and mortality rates of gastric cancer (GC), the impact of demographic transition on the global burden of GC remains unclear. The current study aimed to estimate the global disease burden through 2040 by age, sex, and region. Methods: GC data for incident cases and deaths by age group and sex were taken from The Global Cancer Observatory (GLOBOCAN) 2020. The incidence and mortality rates were predicted through 2040 by fitting a linear regression model over the most recent trend period with the Cancer Incidence in Five Continents (CI5) data. Results: The global population will grow to 9.19 billion by 2040, accompanied by increasing population ageing. The incidence and mortality rates of GC will show a persistent decrease, with an annual percent change of -0.57% for males and -0.65% for females. East Asia and North America will have the highest and lowest age standardized rates, respectively. A slowdown in the growth of incident cases and deaths will be observed worldwide. The proportion of young and middle-aged individuals will decline, while the percentage of the elderly will increase, and the number of males will be almost twice the number of females. East Asia and high human development index (HDI) regions will be heavily burdened by GC. East Asia had 59.85% of the new cases and 56.23% of deaths in 2020;these will increase to 66.93% and 64.37% by 2040, respectively. The interaction between population growth, the change in ageing structure and the decline in incidence and mortality rates will lead to an increased burden of GC. Conclusions: Ageing and population growth will offset the decline in the incidence and mortality rate of GC, resulting in a substantial increase in the number of new cases and deaths. The age structure will continue to change, especially in high HDI regions, requiring more targeted prevention strategies in the future.
文摘癌症是影响人类健康的主要疾病之一,其发病率和死亡率等数据的准确统计对于开展疾病预防及制定干预策略极为重要。GLOBOCAN是国际癌症研究机构(International Agency for Research on Cancer,IARC)的一个项目,统计了世界上185个国家/地区中的36种癌症发病率、死亡率和患病率等相关数据,并且数据会不断更新,为研究者做疾病预测及疾病负担分析提供了宝贵的资料。本文通过对GLOBOCAN数据库架构及数据分析方法的详细介绍,帮助需要的研究者快速获取数据库相关知识,高效快捷地开展相关研究。
基金the Scientific Research Projects of Health Commission of Mianyang City,No.202012.
文摘BACKGROUND Digestive cancer has traditionally been thought of as a disease that mainly occurs in elderly individuals,and it has been ignored in young adults by both patients and physicians.AIM To describe the worldwide profile of digestive cancer incidence,mortality and corresponding trends among 20–39-year-olds,with major patterns highlighted by age,sex,development level,and geographical region.METHODS I performed a population-based study to quantify the burden of young adult digestive cancers worldwide.Global,regional,sex,and country-specific data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2020 were extracted from the GLOBOCAN Cancer Today database.To assess long-term trends in young adult digestive cancer,cancer incidence data and mortality data were obtained from the Cancer in Five Continents Plus database and the World Health Organization mortality database,respectively.The associations between the human development index(HDI)and digestive cancer burden in young adults were evaluated by linear regression analyses.RESULTS In 2020,there were an estimated 19292789 new cancer cases,resulting in 9958133 deaths worldwide,which equated to an age-standardized incidence rate(ASIR)of 5.16 and age-standardized mortality rate(ASMR)of 3.04,accounting for 12.24%of all new cancer cases and 25.26%of all cancer deaths occurring in young adults.The burden was disproportionally greater among males,with male:female ratios of 1.34 for incidence and 1.58 for mortality.The ASIRs were 2.1,1.4,and 1.0 per 100000 people per year,whereas the ASMRs were 0.83,1.1,and 0.62 per 100000 people per year for colorectal,liver,and gastric cancer,respectively.When assessed by geographical region and HDI levels,the cancer profile varied substantially,and a strong positive correlation between the mortality-to-incidence ratio of digestive cancer and HDI ranking was found(R^(2)=0.7388,P<0.001).CONCLUSION The most common digestive cancer types are colorectal,liver and gastric cancer.The global digestiv
文摘近期,世界卫生组织/国际癌症中心团队在A Cancer Journal for Clinicians(CA)杂志发表了最新的全球癌症统计数据。这份全球癌症负担现状的报告重点阐述了185个国家的36种癌症的发病和死亡情况,分析了癌症的区域性差异,并预估全球2018年将新增1810万癌症病例和970万癌症死亡病例。北京市肿瘤防治研究办公室团队对该报告进行了整理,并结合中国肿瘤登记现况进行简要解读。
